<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01805596</url>
  </required_header>
  <id_info>
    <org_study_id>ENTC-18129</org_study_id>
    <nct_id>NCT01805596</nct_id>
  </id_info>
  <brief_title>Effect of Ticagrelor on Endothelial Function</brief_title>
  <official_title>Effect of Ticagrelor on Endothelial Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lawson Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lawson Health Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to assess the function of blood vessels while being treated with different
      types of blood thinners to determine the effect of these medications on blood vessels.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Endothelial Function after 21 days of antiplatelet medication</measure>
    <time_frame>21 days</time_frame>
    <description>The change in endothelial function from baseline will be assessed after 21 days of clopidogrel; the change in endothelial function from baseline will be assessed after 21 days of ticagrelor. This will be measured using RH-PAT units.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute change in endothelial function</measure>
    <time_frame>2 hours</time_frame>
    <description>Endothelial function assessed 2 hours post ticagrelor</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Endothelial Function</condition>
  <arm_group>
    <arm_group_label>clopidogrel-ticagrelor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>21 days clopidogrel followed by 21 days ticagrelor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ticagrelor-clopidogrel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ticagrelor for 21 days followed by clopidogrel for 21 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clopidogrel</intervention_name>
    <arm_group_label>clopidogrel-ticagrelor</arm_group_label>
    <arm_group_label>ticagrelor-clopidogrel</arm_group_label>
    <other_name>Plavix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <arm_group_label>clopidogrel-ticagrelor</arm_group_label>
    <arm_group_label>ticagrelor-clopidogrel</arm_group_label>
    <other_name>Brilinta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age&gt;18 years old

          2. At least two cardiovascular risk factors

          3. Demonstrated endothelial dysfunction

          4. Evidence of coronary artery disease

        Exclusion Criteria:

          1. Second (II) or third (III) degree heart block without a pacemaker

          2. Known active pathological bleeding, history of stroke, or bleeding diathesis

          3. Dyspnea classified as NYHA class III-IV

          4. Need for oral anticoagulants

          5. Clinically significant valvular heart disease

          6. Any concurrent life threatening condition with a life expectancy less than 1 year

          7. History or evidence of drug or alcohol abuse within the last 12 months

          8. Any surgical or medical condition, which in the opinion of the investigator, may place
             the patient at higher risk from his/her participation in the study, or is likely to
             prevent the patient from complying with the requirements of the study or completing
             the study

          9. History of hypersensitivity to any of the study drugs or to medications belonging to
             the same therapeutic class as the study drugs as well as known or suspected
             contraindications to the study drugs.

         10. Latex allergy

         11. History of noncompliance to medical regimens or unwillingness to comply with the study
             protocol

         12. Use of other investigational drugs at the time of enrollment, or within 30 days or 5
             half-lives of enrollment, whichever is longer Positive pregnancy test, breast feeding
             women or women of child bearing potential not using highly effective methods of
             contraception.

         13. Patients who are also taking strong CYP3A4 inhibitors (e.g., ketoconazole,
             clarithromycin, nefazodone, ritonavir, and atazanavir)

         14. patients taking antiplatelet medications which cannot be stopped

         15. severe liver disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shahar Lavi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>London Health Sciences Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2013</study_first_submitted>
  <study_first_submitted_qc>March 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2013</study_first_posted>
  <last_update_submitted>October 4, 2016</last_update_submitted>
  <last_update_submitted_qc>October 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lawson Health Research Institute</investigator_affiliation>
    <investigator_full_name>Shahar Lavi</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>coronary artery disease</keyword>
  <keyword>endothelial function</keyword>
  <keyword>antiplatelet agent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

